Adrian Rabin
Lawyers
Filters
Ascentage Pharma $126.4 million IPO
The IPO is the first life sciences U.S. IPO of 2025 and the first life sciences company listed on the HKEX to complete a U.S. listing
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Uranium Energy $300 million at-the-market offering
The shares are listed on NYSE American
Revolution Medicines $750 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market
ACELYRIN $150 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Labcorp $2 billion senior notes offering
The investment-grade notes are due 2030, 2032 and 2034
Terns Pharmaceuticals $173 million stock and pre-funded warrants offering
The shares are listed on the Nasdaq Global Select Market
Recursion Pharmaceuticals $230 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Sealed Air $400 million senior notes offering and concurrent tender offer
The new high-yield notes are due 2032
Applied Materials $700 million senior notes offering
The investment-grade notes are due 2029